DeutschNewstral
Article
Mmarketwatch.com on 2017-04-14 15:23
Eli Lilly and Incyte stock drops after FDA fails to approve rheumatoid arthritis drug
Related news
- MEli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drugmarketwatch.com
Rheumatoid arthritis drug cuts coronavirus deaths in clinical trial, Eli Lilly saysFox News- MIncyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approvalmarketwatch.com
- MEli Lilly, Incyte shares drop after mixed FDA drug recommendationmarketwatch.com
Eli Lilly, Incyte drug fares well in late-stage researchelkharttruth.com- MGilead shares drop on FDA concerns with similar Eli Lilly, Incyte drugmarketwatch.com
- FFDA arthritis drug rejection hits Eli Lilly sharesft.com
- ELilly starts trials to explore whether its rheumatoid arthritis drug can treat coronaviruseu.indystar.com
- ELilly study shows its drug for rheumatoid arthritis helps in coronavirus treatmenteu.indystar.com
- KTyrosine Kinase JAK Inhibitors Market Growth by Global Key Players:Teva, Incyte, Eli Lilly, Gilead, Novartis, AbbVie, Sanofi, Vertexksusentinel.com
FDA Approves Rheumatoid Arthritis Biosimilarwsj.com
Eli Lillymichronicleonline.com
FDA Gives Emergency Approval To Covid-19 Treatment That Combines Eli Lilly Arthritis Drug With RemdesivirForbes- MShares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery timemarketwatch.com
- Eli Lilly pharmaceutical company starts Phase 3 coronavirus trial with drug used to treat arthritisFox News
- MEli Lilly to study use of arthritis drug to treat COVID-19marketwatch.com
Lilly’s rheumatoid arthritis pill rejected by regulatorsseattletimes.com- ALilly's rheumatoid arthritis pill rejected by regulatorsapnewsarchive.com